Manufacture

Does pharma really need to pay a high price when it comes to synthetic chemistry?

High-level purification maximizes the amount of therapeutic gene payload being delivered with each vector to reduce the risk of immune reaction.

In this eBook, experts give their views on enhancing downstream purification.

Dave Tudor gives an update on CPI’s “Grand Challenges”.

DNA manufacturers must pick up the pace to support the genetic medicine revolution.

A pair of medicines manufacturing initiatives are looking to improve continuous direct compression and clinical trial supply.

How will astronauts make medicines in space?

Cell and gene therapy manufacturing technologies and methods are advancing rapidly, but can regulators keep up?

Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.

The increasing complexity of biologics raises significant manufacturing challenges – not least regarding cost control and downstream purification.